The role of COX-2 in breast and cervical cancer

Progress in Experimental Tumor Research

Volumn 37, Issue , 2003, Pages 90-106

  Dannenberg, Andrew J ^a,b   Howe, Louise R ^a,b,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Strang Cancer Research Laboratory   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN;

ANIMAL; BREAST TUMOR; ENZYMOLOGY; FEMALE; HUMAN; PHYSIOLOGY; REVIEW; UTERINE CERVIX TUMOR;

ANIMALS; BREAST NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; UTERINE CERVICAL NEOPLASMS;

EID: 0043133540     PISSN: 00796263     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000071368     Document Type: Article

References (85)

1. Suh O, Mettlin C, Petrelli NJ: Aspirin use, cancer and polyps of the large bowel. Cancer 1993;72:1171-1177.
2. Thun MJ, Namboodiri MM, Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-1596.
3. Logan RF, Little J, Hawtin PG, Hardcastle JD: Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: Case-control study of subjects participating in the Nottingham faecal occult blood screening programme. Br Med J 1993;307:285-289.
4. Greenberg ER, Baron JA, Freeman DH Jr, Mandel JS, Haile R: Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst 1993;85:912-916.
5. Reeves MJ, Newcomb PA, Trentham-Dietz A, Storer BE, Remington PL: Nonsteroidal antiinflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 1996;5:955-960.
6. Howe LR, Subbaramaiah K, Brown AMC, Dannenberg AJ: Cyclooxygenase-2: A target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001;8:97-l14.
7. Δ716 knockout mice by inhibition of cyclooxygenase-2. Cell 1996;87:803-809.
8. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18563-18569.
9. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, Isakson PC, Verburg KM, Yu SS, Zhao WW, Geis GS: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial. JAMA 1999;282:1921-1928.
10. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-1933.
11. Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M: Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 1980;64:1061-1070.
12. Bennett A, Charlier EM, McDonald AM, Simpson JS, Stamford IF, Zebro T: Prostaglandins and breast cancer. Lancet 1977;ii:624-626.
13. Tan WC, Privett OS, Goldyne ME: Studies of prostaglandins in rat mammary tumors induced by 7,12-dimethylbenz[a]anthracene. Cancer Res 1974;34:3229-3231.
14. Gilhooly EM, Rose DP: The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines. Int J Oncol 1999;15:267-270.
15. Liu XH, Rose DP: Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 1996;56:5125-5127.
16. Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, Dannenberg AJ: Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996;56:4424-4429.
17. Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM: Cyclooxygenase-2 expression in human breast cancer. Int J Oncol 1997;10:503-507.
18. Hwang D, Scollard D, Byrne J, Levine E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90:455-4160.
19. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-635.
20. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT: COX-2 is expressed in human pulmonary, colonic and mammary tumors. Cancer 2000;89:2637-2645.
21. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA: Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002;62:1676-1681.
22. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ: Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer. Evidence for involvement of AP-1 and PEA3. J Biol Chem 2002;277:18649-18657.
23. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T: Expression of cyclooxygenase-l and -2 in human colorectal cancer. Cancer Res 1995;55:3785-3789.
24. Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, White RL, Prescott SM: Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996;93:4816-41820.
25. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S: Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995;55:2556-2559.
26. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-1188.
27. Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA: Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 1996;88:988-993.
28. Paganini-Hill A, Chao A, Ross RK, Henderson BE: Aspirin use and chronic diseases: A cohort study of the elderly. BMJ 1989;299:1247-1250.
29. Friedman GD, Ury HK: Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst 1980;65:723-733.
30. Harris RE, Namboodiri KK, Farrar WB: Nonsteroidal anti-inflammatory drugs and breast cancer. Epidemiology 1996;7:203-205.
31. Schreinemachers DM, Everson RB: Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-146.
32. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA: Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 2000;83:112-120.
33. Badawi AF, el-Sohemy A, Stephen LL, Ghoshal AK, Archer MC: Modulation of the expression of the cyclooxygenase-1 and -2 genes in rat mammary glands: Role of hormonal status and dietary fat. Adv Exp Med Biol 1999;469:119-124.
34. Hamid R, Singh J, Reddy BS, Cohen LA: Inhibition by dietary menhaden oil of cyclooxygenase-1 and -2 in N-nitrosomethylurea-induced rat mammary tumors. Int J Oncol 1999;14:523-528.
35. Nakatsugi S, Ohta T, Kawamori T, Mutoh M, Tanigawa T, Watanabe K, Sugie S, Sugimura T, Wakabayashi K: Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-l-methyl-6-phenylimidazo[4,5-b]pyridine (PhlP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res 2000;91:886-892.
36. Robertson FM, Parrett ML, Joarder FS, Ross M, Abou-Issa HM, Alshafie G, Harris RE: Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Lett 1998;122:165-175.
37. Abou-Issa HM, Alshafie GA, Seibert K, Koki AT, Masferrer JL, Harris RE: Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res 2001;21:3425-3432.
38. Kundu N, Yang Q, Dorsey R, Fulton AM: Increased cyclooxygenase-2 expression and activity in a murine model of metastatic breast cancer. Int J Cancer 2001;93:681-686.
39. Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AMC, Dannenberg AJ: Celecoxib, a selective cyclooxygenase-2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 2002;62:5405-5407.
40. Howe LR, Crawford HC, Subbaramaiah K, Hassell JA, Dannenberg AJ, Brown AMC: PEA3 is upregulated in response to Wnt1 and activates the expression of cyclooxygenase-2. J Biol Chem 2001;276:20108-20115.
41. Noguchi M, Taniya T, Koyasaki N. Kumaki T, Miyazaki I, Mizukami Y: Effects of the prostaglandin synthetase inhibitor indomethacin on tumorigenesis. tumor proliferation, cell kinetics, and receptor contents of 7,12-dimethylbenz[a]anthracene-induced mammary carcinoma in Sprague-Dawley rats fed a high- or low-fat diet. Cancer Res 1991;51:2683-2689.
42. McCormick DL, Madigan MJ, Moon RC: Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res 1985;45:1803-1808.
43. Carter CA, Ip MM, Ip C: A comparison of the effects of the prostaglandin synthesis inhibitors indomethacin and carprofen on 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis in rats fed different amounts of essential fatty acid. Carcinogenesis 1989:10:1369-1374.
44. Carter CA, Milholland RJ, Shea W, Ip MM: Effect of the prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis in rats fed different levels of fat. Cancer Res 1983;43:3559-3562.
45. Abou-el-Ela SH, Prasse KW, Farrell RL, Carroll RW, Wade AE, Bunce OR: Effects of D,L-2-difluoromethylornithine and indomethacin on mammary tumor promotion in rats fed high n-3 and/or n-6 fat diets. Cancer Res 1989;49:1434-1440.
46. Suzui N, Sugie S, Rahman KM, Ohnishi M, Yoshimi N, Wakabayashi K, Mori H: Inhibitory effects of diallyl disulfide or aspirin on 2-amino-l-methyl-6-phenylimidazo[4,5-b]pyridine-induced mammary carcinogenesis in rats. Jpn J Cancer Res 1997;88:705-711.
47. McCormick DL, Moon RC: Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal anti-inflammatory agent. Br J Cancer 1983;48:859-861.
48. Mori H, Sugie S, Rahman W, Suzui N: Chemoprevention of 2-amino-l-methyl-6-phenylimidazo[4,5-b]pyridine-induced mammary carcinogenesis in rats. Cancer Lett 1999;143:195-198.
49. Harris RE, Alshafie GA, Abou-Issa H, Seibert K: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000;60:2101-2103.
50. Alshafie GA, Abou-Issa HM, Seibert K, Harris RE: Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 2000;7:1377-1381.
51. Fulton AM: In vivo effects of indomethacin on the growth of murine mammary tumors. Cancer Res 1984;44:2416-2420.
52. 2. Prostaglandins Leukot Med 1986;23:11-14.
53. Kundu N, Fulton AM: Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 2002;62:2343-2346.
54. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O, Langenbach R: Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000;60:4705-4708.
55. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh U, Tarnawski AS: Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999;5:1418-1423.
56. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716.
57. 2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 1999;59:4574-4577.
58. Yamada M, Kawai M, Kawai Y, Mashima Y: The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat. Curr Eye Res 1999;19:300-304.
59. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311.
60. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN: Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000;105:1589-1594.
61. Tsujii M, Kawano S, DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997;94:3336-3340.
62. Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
63. Harris RE, Robertson FM, Abou-Issa HM, Farrar WB, Brueggemeier R: Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): An extension of the dietary fat hypothesis of breast cancer. Med Hypoth 1999;52:291-292.
64. Purohit A, Singh A, Ghilchik MW, Reed MJ: Inhibition of tumor necrosis factor α-stimulated aromatase activity by microtubule-stabilizing agents, paclitaxel and 2-methoxyestradiol. Biochem Biophys Res Commun 1999;261:214-217.
65. 2 via cyclic AMP, leading to activation of promoter II of the CYPI9 (aromatase) gene. Endocrinology 1996;137:5739-5742.
66. Brueggemeier RW, Richards JA, Joomprabutra S, Bhat AS, Whetstone JL: Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents. J Steroid Biochem Mol Biol 2001;79:75-84.
67. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM: Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 1999;140:27-35.
68. Brodie AM, Lu Q, Long BJ, Fulton A, Chen T, Macpherson N, DeJong PC, Blankenstein MA, Nortier JW, Slee PH, van de Ven J, van Gorp JM, Elbers JR, Schipper ME, Blijham GH, Thijssen JH: Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol 2001;79:41-47.
69. Ryu HS, Chang KH, Yang HW, Kim MS, Kwon HC, Oh KS: High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol 2000;76:320-325.
70. Dong YL, Gangula PR, Fang L, Yallampalli C: Differential expression of cyclooxygenase-1 and -2 proteins in rat uterus and cervix during the estrous cycle, pregnancy, labor and in myometrial cells. Prostaglandins 1996;52:13-34.
71. Wu WX, Ma XH, Smith GC, Koenen SV, Nathanielsz PW: A new concept of the significance of regional distribution of prostaglandin H synthase 2 throughout the uterus during late pregnancy: Investigations in a baboon model. Am J Obstet Gynecol 2000;183:1287-1295.
72. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, Subbaramaiah K, Dannenberg AJ: Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 2001;7:429-434.
73. Formenti S, Felix J, Salonga D, Danenberg K, Pike MC, Danenberg P: Expression of metastases-associated genes in cervical cancers resected in the proliferative and secretory phases of the menstrual cycle. Clin Cancer Res 2000;6:4653-4657.
74. Ishiko O, Sumi T, Yoshida H, Tokuyama O, Wakasa K, Haba T, Ogita S: Cyclooxygenase-2 expression in an adenoid cystic carcinoma of the uterine cervix. Oncol Rep 2001;8:1023-1025.
75. 2 synthesis are up-regulated in carcinomas of the cervix: A possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab 2001;86:2243-2249.
76. Gaffney DK, Holden J, Davis M, Zempolich K, Murphy KJ, Dodson M: Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2001;49:1213-1217.
77. Ishiko O, Sumi T, Yoshida H, Matsumoto Y, Honda K, Deguchi M, Yamada R, Ogita S: Association between overexpression of cyclooxygenase-2 and suppression of apoptosis in advanced cancer of the uterine cervix after cyclic balloon-occluded arterial infusion. Oncol Rep 2001;8:1259-1263.
78. Ferrandina G, Lauriola L, Distefano MG, Zannoni GF, Gessi M, Legge F, Maggiano N, Mancuso S, Capelli A, Scambia G, Ranelletti FO: Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 2002;20:973-981.
79. Sales KJ, Katz AA, Howard B, Soeters RP, Millar RP, Jabbour HN: Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin E receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res 2002;62:424-432.
80. Rao AR, Hussain SP: Modulation of methylcholanthrene-induced carcinogenesis in the uterine cervix of mouse by indomethacin. Cancer Lett 1988;43:15-19.
81. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.
82. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN: Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001;120:1713-17I9.
83. Milas L: Cyclooxygenase-2 enzyme inhibitors as potential enhancers of tumor radioresponse. Semin Radiat Oncol 2001;11:290-299.
84. Subbaramaiah K, Hart JC, Norton L, Dannenberg AJ: Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem 2000;275:14838-14845.
85. Kitagawa H, Noguchi M: Comparative effects of piroxicam and esculetin on incidence, proliferation, and cell kinetics of mammary carcinomas induced by 7,12-dimethylbenz[a]anthracene in rats on high- and low-fat diets. Oncology 1994;51:401-410.